Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study

Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by heart failure (HF) with reduced ejection fraction (HFrEF). HF and type 2 diabetes mellitus (T2DM) frequently coexist, with a prevalence of T2DM of 35%–40% in patients with HF. T2DM is the third co-morbidities in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Armentaro, Giuseppe, D’Arrigo, Graziella, Miceli, Sofia, Cassano, Velia, Perticone, Maria, Maio, Raffaele, Marra, Alberto Maria, Arturi, Franco, Cittadini, Antonio, Tripepi, Giovanni, Sesti, Giorgio, Sciacqua, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174635/
https://www.ncbi.nlm.nih.gov/pubmed/35694400
http://dx.doi.org/10.3389/fphys.2022.897109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174635/
https://www.ncbi.nlm.nih.gov/pubmed/35694400
http://dx.doi.org/10.3389/fphys.2022.897109

Ejemplares similares